Literature DB >> 19486189

A large French prospective cohort of HIV-infected patients: the Nadis Cohort.

Pascal Pugliese1, Lise Cuzin, André Cabié, Isabelle Poizot-Martin, Clotilde Allavena, Claudine Duvivier, Myriam El Guedj, Xavier de la Tribonnière, M A Valantin, P Dellamonica.   

Abstract

OBJECTIVES: The aim of this article is to describe the development of a dynamic French cohort of HIV-infected patients, the methodological issues and decisions made, and the characteristics of the patients currently enrolled.
METHODS: Data are collected during medical encounters. Data quality is ensured by automated checks during data capture, by regular controls, by annual assessments, and by ad hoc processes before any scientific analysis is performed.
RESULTS: In September 2007, 10,458 patients representing 59,383 patient-years of follow-up were followed in our centres, including 446 with a first HIV diagnosis in the past year. Among these recently diagnosed patients, 25.6% presented with late diagnosis. Our cohort included 3017 women (28.8%). The women were less likely to be receiving highly active antiretroviral therapy (HAART) than men, and when treated were less likely to be receiving nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. Our network includes medical centres in overseas territories (1105 patients living overseas). In this particular population, women represented 38.5% of the patients, and the probable route of infection was heterosexual in 75.7% of the patients. Despite epidemiological and social disparities, more patients had nondetectable viral loads when receiving HAART in overseas departments than in metropolitan France.
CONCLUSION: The Nadis Cohort represents a collaboration of major French HIV treatment centres. In September 2007, the cohort database contained up-to-date information on more than 10,000 patients, of whom a significant proportion were women. As a consequence of the choices made when building the cohort and the efforts made to ensure the quality of the database, scientific studies are regularly performed using this cohort.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19486189     DOI: 10.1111/j.1468-1293.2009.00719.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  37 in total

1.  New Surge of Syphilis among Patients Living with Human Immunodeficiency Virus in Martinique in 2015.

Authors:  Alain Putot; Benoît Rozé; Sandrine Pierre-François; Mathilde Pircher; Rosalie Vilain; Charline Miossec; Nicole Desbois; Patrick Hochedez; Karine Guitteaud; Ingrid Laudarin; Sylvie Abel; André Cabié
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

2.  Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection.

Authors:  Alissa Naqvi; Valérie Giordanengo; Brigitte Dunais; Francine de Salvador-Guillouet; Isabelle Perbost; Jacques Durant; Pascal Pugliese; Aline Joulié; Pierre Marie Roger; Eric Rosenthal
Journal:  World J Hepatol       Date:  2015-08-28

3.  Impact of Age-related Comorbidities on Five-year Overall Mortality among Elderly HIV-Infected Patients in the Late HAART Era--Role of Chronic Renal Disease.

Authors:  M Hentzien; M Dramé; C Allavena; C Jacomet; M-A Valantin; A Cabié; L Cuzin; D Rey; P Pugliese; F Bani-Sadr
Journal:  J Nutr Health Aging       Date:  2016-04       Impact factor: 4.075

4.  Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.

Authors:  Caroline Solas; Sylvie Bregigeon; Olivia Faucher-Zaegel; Sylvie Quaranta; Véronique Obry-Roguet; Catherine Tamalet; Bruno Lacarelle; Isabelle Poizot-Martin
Journal:  Br J Clin Pharmacol       Date:  2017-11-28       Impact factor: 4.335

5.  Imputation of the Date of HIV Seroconversion in a Cohort of Seroprevalent Subjects: Implications for Analysis of Late HIV Diagnosis.

Authors:  Paz Sobrino-Vegas; Santiago Pérez-Hoyos; Ronald Geskus; Belén Padilla; Ferrán Segura; Rafael Rubio; Jorge Del Romero; Jesus Santos; Santiago Moreno; Julia Del Amo
Journal:  AIDS Res Treat       Date:  2011-10-15

6.  Economic impact of generic antiretrovirals in France for HIV patients' care: a simulation between 2019 and 2023.

Authors:  Romain Demeulemeester; Nicolas Savy; Michaël Mounié; Laurent Molinier; Cyrille Delpierre; Pierre Dellamonica; Clotilde Allavena; Pascal Pugliesse; Lise Cuzin; Philippe Saint-Pierre; Nadège Costa
Journal:  BMC Health Serv Res       Date:  2022-04-27       Impact factor: 2.908

7.  Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study.

Authors:  F De Salvador-Guillouët; C Sakarovitch; J Durant; K Risso; E Demonchy; P M Roger; E Fontas
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

8.  Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.

Authors:  Isabelle Poizot-Martin; Alissa Naqvi; Véronique Obry-Roguet; Marc-Antoine Valantin; Lise Cuzin; Eric Billaud; Antoine Cheret; David Rey; Christine Jacomet; Claudine Duvivier; Pascal Pugliese; Pierre Pradat; Laurent Cotte
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

9.  Characteristics and consequences of medical care interruptions in HIV-infected patients in France.

Authors:  L Cuzin; P Dellamonica; Y Yazdanpanah; S Bouchez; D Rey; B Hoen; A Cabié
Journal:  Epidemiol Infect       Date:  2016-04-01       Impact factor: 4.434

10.  Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.

Authors:  Hélène Peyriere; Amandine Cournil; Marie-Laure Casanova; Stéphanie Badiou; Jean-Paul Cristol; Jacques Reynes
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.